Vaccination coverage and its determinants in patients with multiple sclerosis—a multicenter cross-sectional study
Background: Complete vaccination coverage is recommended by multiple sclerosis (MS) societies for patients with multiple sclerosis (pwMS) to mitigate infection risks associated with disease-modifying therapies (DMTs). Objectives: To analyze vaccination coverage and its determinants in pwMS compared...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-01-01
|
| Series: | Therapeutic Advances in Neurological Disorders |
| Online Access: | https://doi.org/10.1177/17562864241309806 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832586598257000448 |
|---|---|
| author | Paula Schade Hai-Anh Nguyen Julia Steinle Kerstin Hellwig Teodor Pelea Philipp Franken Birte Elias-Hamp Veit Becker Stefan Merkelbach Stephan Richter Bert Wagner Christian Geis Matthias Schwab Florian Rakers |
| author_facet | Paula Schade Hai-Anh Nguyen Julia Steinle Kerstin Hellwig Teodor Pelea Philipp Franken Birte Elias-Hamp Veit Becker Stefan Merkelbach Stephan Richter Bert Wagner Christian Geis Matthias Schwab Florian Rakers |
| author_sort | Paula Schade |
| collection | DOAJ |
| description | Background: Complete vaccination coverage is recommended by multiple sclerosis (MS) societies for patients with multiple sclerosis (pwMS) to mitigate infection risks associated with disease-modifying therapies (DMTs). Objectives: To analyze vaccination coverage and its determinants in pwMS compared to healthy controls, considering vaccination hesitancy, MS-specific vaccination beliefs, trust in information sources, and the role of general practitioners (GPs). Methods: This cross-sectional multicenter observational study was conducted in six German MS centers. The primary endpoint was a vaccination index (VI) comprising eight standard vaccinations (range 0–1, with higher VI indicating better vaccination coverage). Secondary endpoints included validated measures of general vaccination hesitancy, MS-specific vaccination beliefs, and trust in information sources. Data were collected through questionnaires, vaccination card analysis, and a survey of GPs who vaccinate pwMS. Results: VI tended to be lower in pwMS ( n = 397) compared to healthy controls ( n = 300; 0.58 ± 0.30 vs 0.62 ± 0.31, p = 0.057). In pwMS receiving highly effective DMTs, VI did not differ significantly from those on no/platform DMTs. Vaccination hesitancy was comparably low, with no differences between pwMS and controls. Vaccination hesitancy, beliefs, and trust in information sources explained only 10%–16% of the variance in VI. Among 109 GPs, 82% cited reluctance to vaccinate pwMS due to concerns about MS-related side effects or interactions with DMTs. Conclusion: Despite clear recommendations from MS societies for full vaccination of all pwMS, vaccination coverage remains worryingly low. Approximately half of the patients lack standard vaccination coverage, even those on highly effective DMTs. In fact, vaccination coverage in pwMS tended to be even lower than in healthy controls. Vaccination hesitancy and other intrinsic factors do not sufficiently explain the low vaccination rates. Inconsistent vaccination recommendations from GPs due to uncertainties about vaccine safety and DMT interactions likely contribute. |
| format | Article |
| id | doaj-art-ba5786fc38ab4f97b83709f5503d0be5 |
| institution | Kabale University |
| issn | 1756-2864 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Neurological Disorders |
| spelling | doaj-art-ba5786fc38ab4f97b83709f5503d0be52025-01-25T07:03:43ZengSAGE PublishingTherapeutic Advances in Neurological Disorders1756-28642025-01-011810.1177/17562864241309806Vaccination coverage and its determinants in patients with multiple sclerosis—a multicenter cross-sectional studyPaula SchadeHai-Anh NguyenJulia SteinleKerstin HellwigTeodor PeleaPhilipp FrankenBirte Elias-HampVeit BeckerStefan MerkelbachStephan RichterBert WagnerChristian GeisMatthias SchwabFlorian RakersBackground: Complete vaccination coverage is recommended by multiple sclerosis (MS) societies for patients with multiple sclerosis (pwMS) to mitigate infection risks associated with disease-modifying therapies (DMTs). Objectives: To analyze vaccination coverage and its determinants in pwMS compared to healthy controls, considering vaccination hesitancy, MS-specific vaccination beliefs, trust in information sources, and the role of general practitioners (GPs). Methods: This cross-sectional multicenter observational study was conducted in six German MS centers. The primary endpoint was a vaccination index (VI) comprising eight standard vaccinations (range 0–1, with higher VI indicating better vaccination coverage). Secondary endpoints included validated measures of general vaccination hesitancy, MS-specific vaccination beliefs, and trust in information sources. Data were collected through questionnaires, vaccination card analysis, and a survey of GPs who vaccinate pwMS. Results: VI tended to be lower in pwMS ( n = 397) compared to healthy controls ( n = 300; 0.58 ± 0.30 vs 0.62 ± 0.31, p = 0.057). In pwMS receiving highly effective DMTs, VI did not differ significantly from those on no/platform DMTs. Vaccination hesitancy was comparably low, with no differences between pwMS and controls. Vaccination hesitancy, beliefs, and trust in information sources explained only 10%–16% of the variance in VI. Among 109 GPs, 82% cited reluctance to vaccinate pwMS due to concerns about MS-related side effects or interactions with DMTs. Conclusion: Despite clear recommendations from MS societies for full vaccination of all pwMS, vaccination coverage remains worryingly low. Approximately half of the patients lack standard vaccination coverage, even those on highly effective DMTs. In fact, vaccination coverage in pwMS tended to be even lower than in healthy controls. Vaccination hesitancy and other intrinsic factors do not sufficiently explain the low vaccination rates. Inconsistent vaccination recommendations from GPs due to uncertainties about vaccine safety and DMT interactions likely contribute.https://doi.org/10.1177/17562864241309806 |
| spellingShingle | Paula Schade Hai-Anh Nguyen Julia Steinle Kerstin Hellwig Teodor Pelea Philipp Franken Birte Elias-Hamp Veit Becker Stefan Merkelbach Stephan Richter Bert Wagner Christian Geis Matthias Schwab Florian Rakers Vaccination coverage and its determinants in patients with multiple sclerosis—a multicenter cross-sectional study Therapeutic Advances in Neurological Disorders |
| title | Vaccination coverage and its determinants in patients with multiple sclerosis—a multicenter cross-sectional study |
| title_full | Vaccination coverage and its determinants in patients with multiple sclerosis—a multicenter cross-sectional study |
| title_fullStr | Vaccination coverage and its determinants in patients with multiple sclerosis—a multicenter cross-sectional study |
| title_full_unstemmed | Vaccination coverage and its determinants in patients with multiple sclerosis—a multicenter cross-sectional study |
| title_short | Vaccination coverage and its determinants in patients with multiple sclerosis—a multicenter cross-sectional study |
| title_sort | vaccination coverage and its determinants in patients with multiple sclerosis a multicenter cross sectional study |
| url | https://doi.org/10.1177/17562864241309806 |
| work_keys_str_mv | AT paulaschade vaccinationcoverageanditsdeterminantsinpatientswithmultiplesclerosisamulticentercrosssectionalstudy AT haianhnguyen vaccinationcoverageanditsdeterminantsinpatientswithmultiplesclerosisamulticentercrosssectionalstudy AT juliasteinle vaccinationcoverageanditsdeterminantsinpatientswithmultiplesclerosisamulticentercrosssectionalstudy AT kerstinhellwig vaccinationcoverageanditsdeterminantsinpatientswithmultiplesclerosisamulticentercrosssectionalstudy AT teodorpelea vaccinationcoverageanditsdeterminantsinpatientswithmultiplesclerosisamulticentercrosssectionalstudy AT philippfranken vaccinationcoverageanditsdeterminantsinpatientswithmultiplesclerosisamulticentercrosssectionalstudy AT birteeliashamp vaccinationcoverageanditsdeterminantsinpatientswithmultiplesclerosisamulticentercrosssectionalstudy AT veitbecker vaccinationcoverageanditsdeterminantsinpatientswithmultiplesclerosisamulticentercrosssectionalstudy AT stefanmerkelbach vaccinationcoverageanditsdeterminantsinpatientswithmultiplesclerosisamulticentercrosssectionalstudy AT stephanrichter vaccinationcoverageanditsdeterminantsinpatientswithmultiplesclerosisamulticentercrosssectionalstudy AT bertwagner vaccinationcoverageanditsdeterminantsinpatientswithmultiplesclerosisamulticentercrosssectionalstudy AT christiangeis vaccinationcoverageanditsdeterminantsinpatientswithmultiplesclerosisamulticentercrosssectionalstudy AT matthiasschwab vaccinationcoverageanditsdeterminantsinpatientswithmultiplesclerosisamulticentercrosssectionalstudy AT florianrakers vaccinationcoverageanditsdeterminantsinpatientswithmultiplesclerosisamulticentercrosssectionalstudy |